Genotipo complejo en un paciente con GIST.

id	metarevistapublica_acho_revistacolombianadehematologiayoncologia_27-article-291
record_format	ojs
spelling	Genotipo complejo en un paciente con GIST. Serrano, Silvia Núm. 1 , Año 2012 : Abril Artículo de revista Bogotá: Asociación Colombiana de Hematología y Oncología, 2012- Revista colombiana de hematología y oncología Becerra, Henry Zuluaga, Alirio Aguirre, Diego 1 Álvarez, Johanna Otero, Jorge Carranza, Hernán Vargas, Carlos Acevedo, Andrés Cardona, Andrés Felipe 1 Journal article http://purl.org/coar/resource_type/c_6501 Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors. Am J Surg Pathol. 2004;28(7):889-94. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-47. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF (E600) in benign and malignant human tumours. Oncogene. 2008;27(7):877-95. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-15. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62(23):6997-7000. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54. Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47(10):853-9. Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res. 2001;25(7):571-6. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358-62. Text Daniels M, Lurkin I, Pauli R, Erbstösser E, Hildebrandt U, Hellwig K, et al. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett. 2011;312(1):43-54. Downs-Kelly E, Rubi BP. Gastrointestinal stromal tumors: molecular mechanisms and targeted therapies. Patholog Res Int. 2011;4:1-7. van de Rijn M, Hendrickson MR, Rouse RV. CD34 expression by gastrointestinal tract stromal tumors. Human Pathol. 1994:25(8):766-71. Scarpa M, Bertin M, Ruffolo C, Polese L, D’Amico DF, Angriman I. A systematic review on the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol. 2008;98(5):384-92. Fernández JA, Sánchez Canovas M, Parrilla P. Controversias en el tratamiento de los tumores del estroma gastrointestinal (GIST) primarios. Cir Esp. 2010;88:69-80. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459-65. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11(11):4182-90. Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G, et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA. 2006;103(34):12843-8. info:eu-repo/semantics/article http://purl.org/coar/version/c_970fb48d4fbd8a85 https://revista.acho.info/index.php/acho/article/download/291/261 Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol. 2011;8(3):161-70. Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008;14(10):3204-15. http://purl.org/coar/resource_type/c_2df8fbb1 http://purl.org/redcol/resource_type/ART info:eu-repo/semantics/publishedVersion Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16. Italiano A, Cioffi A, Maki RG, Schöffski P, Rutkowski P, Le Cesne A, et al. Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. J Clin Oncol. 2011;29:abstr 10044. Guo T, Agaram NP, Wong GC, Hom G, D’Adamo D, Maki RG, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007;13(16):4874-81. Cauchi C, Somaiah N, Engstrom P, Litwin S, López M, Lee L, et al. Evaluation of nilotinib (N) in advanced GIST previously treated with imatinibmesylate (IM) and sunitinib (S). J Clin Oncol. 2010;28:15s, abstr 10090. Kindler HL, Campbell NP, Wroblewski K, Maki RG, D’Adamo DR, Chow WA, et al. Sorafenib in patients with imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. J Clin Oncol. 2011;29:abstr 10009. info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Nimeiri HS, Maki RG, Kasza K, D’Adamo D, Chow W, et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol. 2008;26:abstr 10502. Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch. 2010;456(2):111-27. Thuneberg L. Interstitial cells of Cajal: intestinal pacemaker cells? Adv Anat Embryo Cell Biol. 1982;71:1-130. Miranda C, Nucifora M, Molinari M, Conca E, Anania MC, Bordoni A, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012;18(6):1769-76. cKIT 2012-04-01 2012-04-01 00:00:00 2012-04-01 00:00:00 resistance sorafenib molecular pathology BRAF 2256-2877 GIST resistencia sorafenib patología molecular cKIT BRAF GIST application/pdf 2256-2915 Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418(6901):934. Rossi CR, Mocellin S, Mancarelli R, Foletto M, Pilati P, Nitti D, et al. Gastrointestinal stromal tumours: from a surgical to a molecular approach. Int J Cancer. 2003;107(2):171-6. Joensuu H. Second line therapies for the treatment of gastrointestinal stromal tumor. Curr Opin Oncol. 2007;19(4):353- 8. Joensuu H, Roberts P, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344(14):1052-6. Nickl NJ. Gastrointestinal stromal tumors: new progress, new questions. Curr Opin Gastroenterol. 2004;20(5):482-7. Oliveros R, Quintero AP, Sánchez R, Mesa JA. Tumores estromales gastrointestinales (GIST) en el Instituto Nacional de Cancerología (INC) 2000-2008. Rev Col Cancerol. 2011;15(4):1-34. Vargas C, Cardona AF, Carranza H, Otero JM, Reveiz L, Ospina E, et al. Tumores del estroma gastrointestinal (GIST): experiencia en dos instituciones hospitalarias de Bogotá D.C., Colombia (estudio del ONCOLGroup). Rev Col Gastroenterol. 2008;23(3):213-23. Chan JK. Mesenchymal tumours of the gastrointestinal tract: a paradise for acronyms (STUMP, GIST, GANT, and now GIPACT). Implications of c-kit in genesis, and yet another of many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal disease? Adv Anat Pathol. 1999;6(1):19-40. Duffaud F, Blay JY. Gastrointestinal stromal tumors: biology and treatment. Oncology. 2003;65(3):187-97. 77 https://revista.acho.info/index.php/acho/article/view/291 70 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. Henry Becerra - 2012 https://creativecommons.org/licenses/by-nc-sa/4.0 https://doi.org/10.51643/22562915.291 10.51643/22562915.291 Publication
institution	ASOCIACION COLOMBIANA DE HEMATOLOGIA Y ONCOLOGIA
thumbnail	https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADEHEMATOLOGIAYONCOLOGIA/logo.png
country_str	Colombia
collection	Revista Colombiana de Hematología y Oncología
title	Genotipo complejo en un paciente con GIST.
spellingShingle	Genotipo complejo en un paciente con GIST. Serrano, Silvia Becerra, Henry Zuluaga, Alirio Aguirre, Diego Álvarez, Johanna Otero, Jorge Carranza, Hernán Vargas, Carlos Acevedo, Andrés Cardona, Andrés Felipe cKIT resistance sorafenib molecular pathology BRAF GIST resistencia sorafenib patología molecular cKIT BRAF GIST
title_short	Genotipo complejo en un paciente con GIST.
title_full	Genotipo complejo en un paciente con GIST.
title_fullStr	Genotipo complejo en un paciente con GIST.
title_full_unstemmed	Genotipo complejo en un paciente con GIST.
title_sort	genotipo complejo en un paciente con gist.
author	Serrano, Silvia Becerra, Henry Zuluaga, Alirio Aguirre, Diego Álvarez, Johanna Otero, Jorge Carranza, Hernán Vargas, Carlos Acevedo, Andrés Cardona, Andrés Felipe
author_facet	Serrano, Silvia Becerra, Henry Zuluaga, Alirio Aguirre, Diego Álvarez, Johanna Otero, Jorge Carranza, Hernán Vargas, Carlos Acevedo, Andrés Cardona, Andrés Felipe
topic	cKIT resistance sorafenib molecular pathology BRAF GIST resistencia sorafenib patología molecular cKIT BRAF GIST
topic_facet	cKIT resistance sorafenib molecular pathology BRAF GIST resistencia sorafenib patología molecular cKIT BRAF GIST
citationvolume	1
citationissue	1
citationedition	Núm. 1 , Año 2012 : Abril
publisher	Bogotá: Asociación Colombiana de Hematología y Oncología, 2012-
ispartofjournal	Revista colombiana de hematología y oncología
source	https://revista.acho.info/index.php/acho/article/view/291
language
format	Article
rights	info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. Henry Becerra - 2012 https://creativecommons.org/licenses/by-nc-sa/4.0
type_driver	info:eu-repo/semantics/article
type_coar	http://purl.org/coar/resource_type/c_6501
type_version	info:eu-repo/semantics/publishedVersion
type_coarversion	http://purl.org/coar/version/c_970fb48d4fbd8a85
type_content	Text
publishDate	2012-04-01
date_accessioned	2012-04-01 00:00:00
date_available	2012-04-01 00:00:00
url	https://revista.acho.info/index.php/acho/article/view/291
url_doi	https://doi.org/10.51643/22562915.291
issn	2256-2877
eissn	2256-2915
doi	10.51643/22562915.291
citationstartpage	70
citationendpage	77
url2_str_mv	https://revista.acho.info/index.php/acho/article/download/291/261
_version_	1823468243508002816

Genotipo complejo en un paciente con GIST. .

Código QR

Estadísticas y Métricas Alternativas

Títulos similares

Genotipo complejo en un paciente con GIST.
.